Drug development: innovation or imitation deficit?
Journal
British Medical Journal
Subject
Strategy and Entrepreneurship
Publishing details
Publication Year
2012
Abstract
Light and Lexchin argue that the pharmaceutical innovation crisis is a myth.1 Although they correctly diagnose the issue, the drug approval data provided tell only half of the story. To shed more light on drug development trends, we classified US Food and Drug Administration approvals of new drugs (therapeutic new molecular entities) into one of three mutually exclusive categories: first-of-kind drugs to be approved within chemical or …
Available on ECCH
No
